Media stories about C R Bard (NYSE:BCR) have been trending somewhat positive on Tuesday, according to Accern Sentiment. The research group ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. C R Bard earned a coverage optimism score of 0.07 on Accern’s scale. Accern also assigned news stories about the medical instruments supplier an impact score of 46.8482268692161 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

BCR stock opened at $331.24 on Tuesday. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.57. C R Bard has a 52-week low of $222.42 and a 52-week high of $337.73.

C R Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

See Also: Marijuana Stocks

Receive News & Ratings for C R Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard and related companies with's FREE daily email newsletter.